Cost-effectiveness analysis of prophylaxis with emicizumab or bypassing agents in children with severe haemophilia A and high-response inhibitors after immunotolerance failure in Brazil

Article Sidebar

PDF
Published May 29, 2025
DOI: https://doi.org/10.18103/mra.v13i5.6546

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

Luila Clicia Moura Henriques
Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Francisco de Assis Acurcio
Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Ricardo Mesquita Camelo
Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.; Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Mariana Michel Barbosa
Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Augusto Afonso Guerra Júnior
Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Juliana Alvares-Teodoro
Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

Abstract

Background: Emicizumab prophylaxis in children with severe haemophilia A and high-response inhibitor is more effective in preventing spontaneous bleeding when compared with bypassing agents prophylaxis. Brazil has approved emicizumab prophylaxis for high-response inhibitor who failed immune tolerance induction.


Methods: A cost-effectiveness analysis was performed to compare emicizumab prophylaxis with bypassing agents prophylaxis in high-response inhibitor during the first 5 years of treatment after immune tolerance induction failure, from the perspective of the Brazilian Ministry of Health (payer). The analysis included a 5-year-old male with high-response inhibitor (baseline weight: 20 kg). We obtained the regimens and costs (in US dollars, adjusted for Purchasing Power Parity) from the recommendations of the Brazilian Ministry of Health and the manufacturer’s package insert and purchasing information, respectively, for both emicizumab and bypassing agents prophylaxis, and the treatment of bleeding events with bypassing agents. We retrieved information on the frequency and treatment of bleeding during prophylaxis from the literature. The sensitivity analysis considered the regimen for prophylaxis and on-demand with bypassing agents and emicizumab, the probability of using a specific type of bypassing agents, and the costs associated with emicizumab and bypassing agents. Moreover, in the sensitivity analysis for emicizumab prophylaxis, we assumed settings with waste (amount of residual emicizumab discarded based on the weight regimen and vial availability) and without waste.


Results: The cost of emicizumab prophylaxis was US$1,012,021.4/ high-response inhibitor with 1.0 bleedings/ high-response inhibitor. Bypassing agents’ prophylaxis costs US$3,659,926.2/ high-response inhibitor with 16.5 bleedings/ high-response inhibitor. The incremental cost-effectiveness ratio was US$170,832.6 per bleed averted, favoring emicizumab prophylaxis. Emicizumab prophylaxis remained dominant after sensitivity analyses. The product regimen variables for bypassing agents prophylaxis and the likelihood of bypassing agents use had a high impact on incremental cost. Waste and on-demand bypassing agents doses had a minimal impact on incremental cost.


Conclusions: In high-response inhibitor, during the first 5 years following immune tolerance induction failure, emicizumab prophylaxis was a dominant option compared to bypassing agents’ prophylaxis, as per the Brazilian setting.

Keywords: haemophilia A, inhibitor, prophylaxis, emicizumab, bypass agent, cost-effectiveness analysis, Brazil

Article Details

How to Cite
HENRIQUES, Luila Clicia Moura et al. Cost-effectiveness analysis of prophylaxis with emicizumab or bypassing agents in children with severe haemophilia A and high-response inhibitors after immunotolerance failure in Brazil. Medical Research Archives, [S.l.], v. 13, n. 5, may 2025. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/6546>. Date accessed: 20 june 2025. doi: https://doi.org/10.18103/mra.v13i5.6546.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 13 No 5 (2025): Vol.13, Issue 5, May 2025
Section
Research Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1 Srivastava A, Santagostino E, Dougall A et al. WFH Guidelines for the Management of Haemophilia, 3rd edition. Haemophilia.2020; 26(S6):1–158.
2. Federação Brasileira de Hemofilia. 2023. Caxias do Sul. FBH. Relatório Anual 2023. Disponível em: https://www.hemofiliabrasil.org.br
3. Ljung R, Auerswald G, Benson G et al. Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients. Eur J Haematol.2019;102(2):111–122.
4. Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on‐demand with bypass treatment. Haemophilia.2015; 21(3):310–319.
5. Brasil. Imunotolerância: protocolo de uso de indução de imunotolerância para pacientes com hemoἀlia A e inibidor. 2015. Ministério da Saúde, Secretaria de atenção à saúde, Departamento de Atenção Especializada e temática.
6. Oldenburg J, Young G, Santagostino E, Escuriola Ettingshausen C. The importance of inhibitor eradication in clinically complicated haemophilia A patients. Expert Rev Hematol. 2018;11(11):857–862.
7. Oldenburg J, Mahlangu JN, Kim B et al. Emicizumab Prophylaxis in Haemophilia A with Inhibitors. N Engl J Med. 2017; 377(9):809–818.
8. Mahlangu J, Oldenburg J, Paz-Priel I et al. Emicizumab Prophylaxis in Patients Who Have Haemophilia A without Inhibitors. N Engl J Med. 2018;379(9):811–822.
9. Young G, Liesner R, Chang T et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with haemophilia A with inhibitors. Blood. 2019;134(24):2127–2138.
10. Pipe SW, Shima M, Lehle M et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019; 6(6):e295–e305.
11. Callaghan MU, Negrier C, Paz-Priel I et al. Long-term outcomes with emicizumab prophylaxis for haemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021; 137(16):2231–2242.
12. Muniz RL, Camelo RM, Araújo MS et al. Efficacy/effectiveness and safety of emicizumab prophylaxis of people with haemophilia A: a systematic review and meta-analysis. Expert Rev Hematol. 2023;16(12):1087–1097.
13. World Federation of Haemophilia. 2024. Report on the Annual Global Survey 2023, https://www1.wfh.org/publications/files/pdf-2525.pdf (Accessed on 14 April 2025)
14. Camelo RM, Dias MM, Caram‐Deelder C et al. Time between inhibitor detection and start of immune tolerance induction: Association with outcome in the BrazIT study. J Thromb Haemost. 2022;20(11):2526–2537.
15. Brasil. CONITEC (Comissão Nacional de Incorporação de Tecnologia). Emicizumabe para tratamento de indivíduos com hemofilia A e inibidores do fator VIII refratários ao tratamento de imunotolerância. 2019. Brasília, Brasil. Ministério da Saúde.
16. Camelo RM, Barbosa MM, Araújo MS et al. Economic Evaluation of Immune Tolerance Induction in Children With Severe Haemophilia A and High-Responding Inhibitors: A Cost-Effectiveness Analysis of Prophylaxis With Emicizumab. Value Health Reg Issues. 2023; 34:31–39.
17. Camelo RM, Barbosa MM, Henriques LCM et al. Emicizumab prophylaxis for people with haemophilia A: Waste estimation and the Brazilian perspective. Saudi Pharm J. 2023;31(12):101867.
18. Tabela 2645: Estimativas populacionais das medianas de altura e peso de crianças, adolescentes e adultos, por sexo, situação do domicílio e idade - Brasil e Grandes Regiões. https://sidra.ibge.gov.br/tabela/2645.
19.. Hoffmann-La Roche. HEMLIBRA ® (emicizumab injection) HEMLIBRA ® emicizumab injection. 2018.
20. Brasil. Ministério da Saúde. Secretaria de Atenção a Saúde. Departamento de Atenção Especializada e Temática. Manual de Hemofilia. 2015. https://bvsms.saude.gov.br/bvs/publicacoes/manual_hemofilia_2 ed.pdf.
21 Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in haemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109(2):546–551.
22. López-Fernández MF, Roca CA, Álvarez-Román MT et al. Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors. Thromb Haemost. 2016;115(05):872–895.
23. Linari S, Castaman G.

Concomitant Use of rFVIIa and Emicizumab in People with Haemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence

. Ther Clin Risk Manag. 2020;16:461–469.
24. Oldenburg J, Shima M, Kruse‐Jarres R et al. Outcomes in children with haemophilia A with inhibitors: Results from a noninterventional study. Pediatr Blood Cancer. 2020;67(10)
25. Ferreira AA, Brum IV, Souza JV de L, Leite ICG. Cost analysis of haemophilia treatment in a Brazilian public blood center. Cad Saude Colet. 2020;28(4):556–566.
26. BPS - Banco de Preços em Saúde. https://bps.saude.gov.br/login.jsf.
27. Listas de preços de medicamentos — Agência Nacional de Vigilância Sanitária - Anvisa. https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/cmed/precos.
28. OECD (2024), Purchasing power parities (PPP) (indicator). doi: 10.1787/1290ee5a-en (Accessed on 10 April 2024).
29. Cortesi PA, Castaman G, Trifirò G et al. Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors. Thromb Haemost. 2020;120(02):216–228.
30. Shen M, Chou S, Chiou S et al. Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan. Haemophilia. 2023;29(6):1499–1508.
31. Bukkems LH, Fischer K, Kremer-Hovinga I et al. Emicizumab Dosing in Children and Adults with Haemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen. Thromb Haemost. 2022;122(02):208–215.
32. Mannucci PM, Hermans C. Low‐dose emicizumab for more equitable access to prophylaxis in resource limited countries. Haemophilia. 2024;30(3):575–576.
33. Chuansumrit A, Sirachainan N, Jaovisidha S et al. Effectiveness of monthly low dose emicizumab prophylaxis without 4‐week loading doses among patients with haemophilia A with and without inhibitors: A case series report. Haemophilia. 2023;29(1):382–385.
34, Bansal S, Donners AAMT, Fischer K et al. Low dose emicizumab prophylaxis in haemophilia a patients: A pilot study from India. Haemophilia. 2023;29(3):931–934.
35. Srivastava A, Iorio A. Lower-dose emicizumab prophylaxis: can less be more? J Thromb Haemost. 2024;22(4):922–925.
36. Liu G, Huang K, Li G et al. Real-world experience of emicizumab prophylaxis in young children with haemophilia A: retrospective data from China. Front Pediatr. 2022 Oct 19;10:992267. doi: 10.3389/fped.2022.992267.
37. Donners AAMT, van der Zwet K, Rademaker CMA, Egberts TCG, Schutgens REG, Fischer K. The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste. Res Pract Thromb Haemost. 2023;7(2):100074.
38. Hatswell AJ, Porter JK. Reducing Drug Wastage in Pharmaceuticals Dosed by Weight or Body Surface Areas by Optimising Vial Sizes. Appl Health Econ Health Policy. 2019;17(3):391–397.
39. Damuzzo V, Russi A, Chiumente M et al. Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy. J Oncol Pharm Pract. 2019;25(4):787–792.
40. Ripoll Gallardo A, Meneghetti G, Ragazzoni L et al. Multiple withdrawals from single-use vials: A study on sterility. Int J Pharm. 2015;485(1–2):160–163.
41. Matsushita T, Shapiro A, Abraham A et al. Phase 3 Trial of Concizumab in Haemophilia with Inhibitors. N Engl J Med. 2023;389(9):783–794.
42. Mahlangu J, Luis Lamas J, Cristobal Morales J et al. Long‐term safety and efficacy of the anti‐tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results. Br J Haematol. 2023;200(2):240–248.
43. Young G, Srivastava A, Kavakli K et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. The Lancet. 2023;401(10386):1427–1437.
44. Nunes AA, Rodrigues BSC, Soares EM, Soares S, Miranzi SSC. Qualidade de vida de pacientes hemofílicos acompanhados em ambulatório de hematologia. Rev. Bras. Hematol. Hemoter. 2009;31 (6). https://doi.org/10.1590/S1516-84842009005000085 (Accessed on 14 April 2025).
45. Jiménez‐Yuste V, Rodríguez‐Merchán EC, Matsushita T, Holme PA. Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery. Haemophilia. 2021;27(4):519–530.